FM19G11

FM19G11 is a hypoxia-inducible factor-1-alpha (HIF-1α) inhibitor, and it inhibits hypoxia-induced luciferase activity with an IC₅₀ of 80 nM in HeLa cells. FM19G11 modulates other signaling pathways, including mTOR and PI3K/Akt/eNOS, when the HIF-1α pathway is inactivated under normoxic conditions^[1][2]. IC50 & Target: HIF-1α^[1] In Vitro: FM19G11 (30-300 nM) inhibits HIFα proteins in the HeLa cell lines^[1].
FM19G11 (500 nM) promotes oligodendrocyte differentiation under hypoxia^[1].
FM19G11 (300 nM; 3 days) suppresses the mRNA levels of O⁶-methylguanine DNA-methyltransferase (MGMT) significantly in hypoxic GBM‐XD, hypoxic T98G, and normoxic T98G cells^[2].
M19G11 (300 nM; 3 days) significantly enhances the pro‐apoptotic effect of temozolomide (TMZ), although FM19G11 does not induce apoptosis by itself^[2]. In Vivo: FM19G11 ( intramedullary injection; 1-8 weeks) improves locomotion in severe spinal cord injury (SCI)^[3].
FM19G11 ( intramedullary injection; 8 weeks) induces the expression of GAP43, an axon growth marker, and RIP, a marker for myelinated oligodendrocytes at the injury^[3].